OST-499 is under clinical development by Oncostellae and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OST-499’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OST-499 overview

OST-502 is under development for the treatment of colorectal cancer, immune activation and solid tumors. The drug candidate is a new chemical entity (NCEs). It is administered through oral route. It acts by targeting glucocorticoid receptor (GR). It was under development for the treatment of castration-resistant prostate cancer.

Oncostellae overview

Oncostellae, is a biotechnology company that focused on development of small molecule drugs for the treatment of cancer. The company is headquartered in Spain.

For a complete picture of OST-499’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.